Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J.

J Clin Invest. 2014 May 1;124(5):2037-49. doi: 10.1172/JCI72522. Epub 2014 Apr 8.

PMID:
24713656
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.

Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J.

Cancer Res. 2014 May 1;74(9):2444-54. doi: 10.1158/0008-5472.CAN-13-2136. Epub 2014 Mar 7.

PMID:
24607842
[PubMed - indexed for MEDLINE]
3.

Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.

Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N.

BMC Cancer. 2012 Jul 23;12:309. doi: 10.1186/1471-2407-12-309.

PMID:
22824143
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.

Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM.

Clin Cancer Res. 2009 Jul 1;15(13):4423-30. doi: 10.1158/1078-0432.CCR-09-0473. Epub 2009 Jun 16.

PMID:
19531623
[PubMed - indexed for MEDLINE]
Free Article
5.

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.

Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.

BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.

PMID:
22436374
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC.

Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A.

J Thorac Oncol. 2013 Mar;8(3):301-8. doi: 10.1097/JTO.0b013e318282def7.

PMID:
23370317
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.

PMID:
22964644
[PubMed - indexed for MEDLINE]
8.

EphA2 in the early pathogenesis and progression of non-small cell lung cancer.

Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM.

Cancer Prev Res (Phila). 2009 Dec;2(12):1039-49. doi: 10.1158/1940-6207.CAPR-09-0212. Epub 2009 Nov 24.

PMID:
19934338
[PubMed - indexed for MEDLINE]
9.

Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.

Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, Aziz K, Cho YJ, Tran PT, Rudin CM.

Mol Cancer Res. 2013 Apr;11(4):329-38. doi: 10.1158/1541-7786.MCR-12-0456. Epub 2013 Jan 30.

PMID:
23364532
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.

Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA.

Am J Pathol. 2012 Jul;181(1):111-20. doi: 10.1016/j.ajpath.2012.03.026. Epub 2012 May 23. Erratum in: Am J Pathol. 2012 Nov;181(5):1889.

PMID:
22634180
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo.

Xu CM, Liu WW, Liu CJ, Wen C, Lu HF, Wan FS.

Cancer Gene Ther. 2013 Aug;20(8):453-60. doi: 10.1038/cgt.2013.40. Epub 2013 Aug 9.

PMID:
23928732
[PubMed - indexed for MEDLINE]
12.

Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation.

Paleari L, Catassi A, Ciarlo M, Cavalieri Z, Bruzzo C, Servent D, Cesario A, Chessa L, Cilli M, Piccardi F, Granone P, Russo P.

Cell Prolif. 2008 Dec;41(6):936-59. doi: 10.1111/j.1365-2184.2008.00566.x. Erratum in: Cell Prolif. 2009 Aug;42(4):568. Cell Prolif. 2009 Feb;42(1):122.

PMID:
19040571
[PubMed - indexed for MEDLINE]
13.

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD.

Cancer Res. 2005 Oct 15;65(20):9455-62.

PMID:
16230409
[PubMed - indexed for MEDLINE]
Free Article
14.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.

PMID:
24045185
[PubMed - indexed for MEDLINE]
15.

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.

Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Int J Cancer. 2012 Apr 15;130(8):1733-44. doi: 10.1002/ijc.26164. Epub 2011 Aug 3.

PMID:
21544811
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL, Date H.

Lung Cancer. 2012 Jun;76(3):431-8. doi: 10.1016/j.lungcan.2011.12.004. Epub 2012 Jan 10.

PMID:
22236865
[PubMed - indexed for MEDLINE]
17.

Proteins kinase Cɛ is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes.

Caino MC, Lopez-Haber C, Kim J, Mochly-Rosen D, Kazanietz MG.

Oncogene. 2012 May 17;31(20):2593-600. doi: 10.1038/onc.2011.428. Epub 2011 Sep 26.

PMID:
21996750
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.

Yuan W, Chen Z, Chen Z, Wu S, Guo J, Ge J, Yang P, Huang J.

Neoplasma. 2012;59(1):105-13.

PMID:
22103904
[PubMed - indexed for MEDLINE]
19.

Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing.

Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG, Longley DB.

Cell Death Differ. 2009 Oct;16(10):1352-61. doi: 10.1038/cdd.2009.76. Epub 2009 Jun 19.

PMID:
19543235
[PubMed - indexed for MEDLINE]
Free Article
20.

EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.

Tandon M, Vemula SV, Sharma A, Ahi YS, Mittal S, Bangari DS, Mittal SK.

J Gene Med. 2012 Feb;14(2):77-89. doi: 10.1002/jgm.1649.

PMID:
22228563
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk